Buymed Expands Strategic Presence in Thailand with GED and Organon

Buymed recently strengthened partnerships with two leading pharmaceutical companies in Thailand: Great Eastern Drug (GED) and Organon Thailand. These strategic conversations represent significant steps in Buymed's regional expansion and demonstrate the company's commitment to building sustainable, long-term partnerships across Southeast Asia.

Building Regional Growth Through Strategic Partnerships

Buymed recently completed a strategic visit to Thailand, engaging with two key partners: Great Eastern Drug (GED), part of the Unilab Group, and Organon Thailand. These conversations represent significant steps in Buymed's regional expansion strategy and demonstrate the company's commitment to building sustainable, long-term partnerships across Southeast Asia.

 

Partnership with Great Eastern Drug: Scaling Digital Healthcare Solutions

Great Eastern Drug's position as a leading pharmaceutical distributor in Thailand made this partnership discussion particularly strategic. The focus centered on leveraging Buymed's digital B2B healthcare ecosystem to drive portfolio growth and market penetration.

Strategic Initiatives:

•       Introduction of Buymed's scalable digital B2B healthcare ecosystem and regional growth capabilities

•       Development of data-driven strategies to accelerate GED portfolio growth across Thailand

•       Focus on expanding market access in underpenetrated regions and strengthening coverage beyond major urban centers

•       Identification of growth opportunities for both established products and newly launched offerings

Market Development Approach: The discussion emphasized Buymed's capability to move beyond traditional distribution. By combining real-time data analytics with direct market access, Buymed enables partners like GED to make informed decisions about market penetration and resource allocation. This approach has proven effective in identifying high-potential regions and optimizing product mix for different market segments.

Partnership with Organon Thailand: Sustaining Strong Momentum

Organon Thailand's strong H1/2026 performance demonstrated the effectiveness of close collaboration between both teams. The partnership review focused on understanding what drove success and how to replicate and expand these results.

2026 Performance Review:

•       Comprehensive review of H1/2026 business performance and positive growth momentum

•       Analysis of collaboration strategies that contributed to strong results

•       Identification of best practices for scaling across the portfolio

H2/2026 and Beyond:

•       Development of H2/2026 growth targets and expansion plans

•       Strategic planning for market presence scaling and portfolio expansion

•       Launch of brand activation campaigns and commercial initiatives to strengthen consumer engagement

•       Reinforcement of Organon as a key strategic partner for expanding contraceptive and allergy portfolios

Strategic Portfolio Focus: Organon's strength in contraceptive and allergy categories positions them well for market growth. Buymed's support focuses on ensuring these categories receive appropriate market coverage, consumer engagement, and retail support to maintain competitive positioning.

The Buymed Model: More Than Distribution

These partnerships illustrate Buymed's evolution from traditional distribution to strategic market development. Key differentiators include:

•       Digital Integration: Combining B2B digital platforms with on-ground execution capabilities

•       Data-Driven Execution: Real-time analytics enabling faster decision-making and market responsiveness

•       Regional Scalability: Proven ability to execute strategies across multiple markets while maintaining local relevance

•       Partnership Commitment: Long-term focus on partner success rather than transactional relationships

Regional Growth Strategy

Thailand represents a critical market in Buymed's Southeast Asian expansion. The partnerships with GED and Organon reflect a broader strategy of:

1.    Market Penetration: Expanding beyond major urban centers to capture growth in secondary and tertiary markets

2.    Portfolio Optimization: Ensuring efficient product mix and market coverage across diverse customer segments

3.    Capability Building: Strengthening partner capabilities through data insights and operational support

4.    Sustainable Growth: Building foundations for long-term market development rather than short-term gains

Looking Forward

The successful engagement with GED and Organon Thailand demonstrates Buymed's ability to attract and retain strategic partnerships. As both relationships move forward, the focus remains on execution excellence, market penetration, and sustainable growth.

Through these partnerships, Buymed continues to establish itself as a preferred partner for pharmaceutical companies seeking to expand their presence in Southeast Asia. By combining scalable digital solutions with deep market understanding and genuine commitment to partner success, Buymed is building the foundation for regional pharmaceutical distribution excellence.